Cytomed Therapeutics Announced That The Intellectual Property Corporation Of Malaysia Has Granted A Patent For Its Chimeric Antigen Receptor Gamma Delta T Cell Technology, Which Targets Solid And Hematological Tumors
Portfolio Pulse from Benzinga Newsdesk
Cytomed Therapeutics has been granted a patent by the Intellectual Property Corporation of Malaysia for its Chimeric Antigen Receptor Gamma Delta T Cell (CAR GDTC) technology, aimed at treating solid and hematological tumors.
January 29, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cytomed Therapeutics' newly granted patent in Malaysia for its CAR GDTC technology could enhance its intellectual property portfolio and potentially increase its market value.
The grant of a patent typically strengthens a company's competitive position by protecting its technology from being replicated by competitors. This can lead to increased investor confidence and potential partnerships or licensing deals, which may have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80